Skip to content

NanoViricides closing in on COVID-19 drug

September 4, 2020

During a corporate presentation at the LD 500 investor conference yesterday, NanoViricides (NYSEMKT:NNVC) President & Executive Chairman Anil Diwan, Ph.D., stated that the company is close to selecting a top clinical candidate for the treatment of COVID-19.

He said that preclinical testing in an animal model showed that the company’s candidates were highly effective against a related coronavirus that uses the same ACE2 receptor as SARS-CoV-2 to infect healthy cells.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: